Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Prostate Cancer

PSMA-Targeted Imaging Agent Posluma Approved to Aid in Prostate Cancer Detection

Diana Ernst, RPh

June 2, 2023

The approval was based on data from the LIGHTHOUSE and SPOTLIGHT clinical trials.

ASCT remains the only curative therapy for patients with MDS.

Lupus Nephritis

CD19-CAR T Cell Therapy Fast Tracked for Systemic Lupus Erythematosus

Diana Ernst, RPh

May 5, 2023

CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell therapy.

Chronic Kidney Disease (CKD)

Filspari Granted Accelerated Approval to Reduce Proteinuria in IgA Nephropathy

Diana Ernst, RPh

February 24, 2023

Sparsentan is an endothelin and angiotensin II receptor antagonist.

Chronic Kidney Disease (CKD)

Recall of Sodium Bicarbonate Injection Due to Vial Breakage Expanded

Diana Ernst, RPh

December 1, 2022

The recalled product was distributed between October 26, 2021 and August 10, 2022.

Chronic Kidney Disease (CKD)

FDA Needs Additional Time to Review Sparsentan, Tofersen Applications

Diana Ernst, RPh

October 19, 2022

The target action dates have been extended by 3 months to allow for extra time to review the applications.

Benign Prostatic Hyperplasia (BPH)

Drug Repurposing Study Shows PDE5 Inhibitors Do Not Reduce Dementia Risk

Diana Ernst, RPh

October 14, 2022

By identifying existing medications that may be repurposed for dementia, clinicians may be able to provide faster treatment for those in need.

Chronic Kidney Disease (CKD)

Kerendia Label Updated With CV Outcomes Data From the FIGARO-DKD Study

Diana Ernst, RPh

September 2, 2022

Finerenone reduced the incidence of the primary composite endpoint of CV death, nonfatal MI, nonfatal stroke or hospitalization for heart failure by 13%.